Abstract Library

#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?

Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kaemmerer D, Trwznik M, Hörsch D, Baum R, Hommann M,

Keywords: Surgery, Primary tumor, PRRT, Grading,

#1827 Primary Tumor Resection Results in Superior Overall Survival after Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Neoplasms

Introduction: Peptide receptor radionuclide therapy (PRRT) is an highly effective therapeutic option to treat advanced neuroendocrine neoplasms (NEN). However, it is still unclear whether resection of primary tumors improves overall survival (OS) after PRRT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kaemmerer D

Authors: Kaemmerer D, Twrznik M, Hommann M, Hörsch D, Baum R,

Keywords: PRRT, surgery,

#1723 Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lupp A

Authors: Mai R, Kaemmerer D, Sänger J, Neubauer E, Schulz S,

Keywords: somatostatin receptor, CXCR4,

#1570 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years

Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Niepsch K, Kaemmerer D, Hommann M,

Keywords: PRRT, Survival, PET/CT,

#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)

Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lock A

Authors: Lock A, Wirtz R, Kaemmerer D, Haugvik S, Kure E,

Keywords: PREDICT-Study, everolimus, pNEN, gene signature, predictive marker,